Diversified Trust Co Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Diversified Trust Co reduced its position in Pfizer Inc. (NYSE:PFE) by 7.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 104,818 shares of the biopharmaceutical company’s stock after selling 8,687 shares during the period. Diversified Trust Co’s holdings in Pfizer were worth $2,781,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PFE. Oliver Luxxe Assets LLC increased its holdings in shares of Pfizer by 2.2% in the 4th quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 401 shares in the last quarter. Neville Rodie & Shaw Inc. boosted its position in shares of Pfizer by 8.7% during the fourth quarter. Neville Rodie & Shaw Inc. now owns 104,728 shares of the biopharmaceutical company’s stock valued at $2,779,000 after buying an additional 8,365 shares during the last quarter. Pensionfund Sabic increased its holdings in Pfizer by 41.7% in the 4th quarter. Pensionfund Sabic now owns 85,000 shares of the biopharmaceutical company’s stock worth $2,255,000 after buying an additional 25,000 shares in the last quarter. Nordea Investment Management AB raised its position in Pfizer by 36.1% in the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after buying an additional 1,080,822 shares during the last quarter. Finally, Central Pacific Bank Trust Division lifted its stake in Pfizer by 95.1% during the 4th quarter. Central Pacific Bank Trust Division now owns 18,118 shares of the biopharmaceutical company’s stock valued at $481,000 after acquiring an additional 8,832 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Guggenheim lowered their target price on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $32.15.

Pfizer Stock Performance

Shares of NYSE PFE opened at $27.12 on Wednesday. The stock has a market cap of $153.69 billion, a PE ratio of 36.65, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a fifty day moving average price of $26.27 and a 200-day moving average price of $28.07. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the business posted ($0.17) EPS. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.34%. Pfizer’s payout ratio is currently 232.43%.

Insiders Place Their Bets

In related news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.